Caribou Biosciences (CRBU) Total Non-Current Liabilities (2020 - 2022)

Caribou Biosciences (CRBU) has 3 years of Total Non-Current Liabilities data on file, last reported at $72.9 million in Q4 2022.

• Total Non-Current Liabilities for Q4 2022 came in at $72.9 million, up 33.72% year-over-year; the trailing twelve-month figure through Dec 2022 was $72.9 million (up 33.72% YoY), and the FY2022 annual result was $72.9 million, up 33.72% from the prior year.
• Total Non-Current Liabilities slipped to $72.9 million in Q4 2022 per CRBU's latest filing, from $74.7 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $74.7 million in Q3 2022 and troughed at $18.0 million in Q4 2020.
• A 3-year average of $60.1 million and a median of $65.1 million in 2021 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities soared 203.12% in 2021, then surged 30.14% in 2022.
• A 3-year view of Total Non-Current Liabilities shows it stood at $18.0 million in 2020, then soared by 203.12% to $54.5 million in 2021, then jumped by 33.72% to $72.9 million in 2022.
• Business Quant data shows CRBU's Total Non-Current Liabilities at $72.9 million in Q4 2022, $74.7 million in Q3 2022, and $73.5 million in Q2 2022.